PleoPharma, Inc., a privately held company focused on cannabis-related health issues, announced today, the presentation of data from their Phase 2b multicenter, randomized, double-blind, multi-dose, placebo-controlled clinical trial of titrating doses of PP-01 for the mitigation of Cannabis Withdrawal Syndrome (CWS) in participants with Cannabis Use Disorder (CUD) at the 2025 annual meeting of The College on Problems of Drug Dependence in New Orleans, LA.

New Patent Issued on April 8, 2025 Patent Protection to March 2041 PHOENIXVILLE, Pa., April 16, 2025 /PRNewswire/ -- PleoPharma, Inc....

A POTENTIAL FIRST IN TREATMENT Fast Track Designation highlights the potential of PP-01 to address a serious and unmet need for patients...

PHOENIXVILLE, Pa., Nov. 18, 2024 /PRNewswire/ -- PleoPharma, Inc., a privately held company focused on cannabis-related health issues

PHOENIXVILLE, Pa., Oct. 7, 2024  PleoPharma, Inc., a privately held company focused on Cannabis-related health issues, announced today that

PHOENIXVILLE, Pa., Sept. 19, 2024 -- PleoPharma, Inc., a privately held company focused on cannabis related health issues, announced today..

PHOENIXVILLE, Pa., Sept. 5, 2024 -- PleoPharma, Inc., a privately held company focused on cannabis related health issues, announced today...